Archives

Perfusfind S.L.

Abstract Introduction It remains unclear whether patients who will not accept allogeneic blood transfusion can be managed successfully with veno-arterial (V-A) extracorporeal membrane oxygenation (ECMO). The objective of our study..

Perfusfind S.L.

Abstract Venoarterial extracorporeal membrane oxygenation (V-A ECMO) is increasingly used in cardiogenic shock for rapid stabilization and bridging towards recovery, long-term mechanical circulatory support or transplant. Although technological advances have..

Perfusfind S.L.

Abstract First described early in the pandemic, coronavirus disease 2019 (COVID-19)-associated fulminant myocarditis can present with arrhythmias and cardiogenic shock, but may be treatable with mechanical circulatory support, such as..

Perfusfind S.L.

Abstract Venoarterial extracorporeal membrane oxygenation (ECMO) is used in cardiogenic shock refractory to inotropic support and intra-aortic balloon pump (IABP) support. Peripheral ECMO can lead to ventricular distention, and IABP..

Perfusfind S.L.

Abstract During refractory cardiogenic shock and cardiac arrest, veno‑arterial extracorporeal membrane oxygenation (VA‑ECMO) is used to restore a circulatory output. However, it also impacts significantly arterial oxygenation. Recentguidelines of the..

Perfusfind S.L.

Abstract Venoarterial extracorporeal membrane oxygenation (VA ECMO) has been increasingly applied in patients with cardiogenic shock in recent years. Nevertheless, many patients cannot be successfully weaned from VA ECMO support..

Perfusfind S.L.

Abstract The use of temporary mechanical circulatory support in cardiogenic shock has increased dramatically despite a lack of randomized controlled trials or evidence guiding clinical decision-making. Recommendations from professional societies..

Perfusfind S.L.

Abstract Purpose of review  Cardiogenic shock is a condition that is characterized by end-organ hypoperfusion secondary to reduced cardiac output, and is associated with substantial mortality. The mainstay of therapy..

Perfusfind S.L.

Abstract Purpose Venoarterial  (VA ECMO) effectively supports refractory  (rCS), and sustains macro- and . We investigated the respective impact of increasing VA ECMO flow or  dose on microcirculation in stabilized VA ECMO–treated patients with..

Perfusfind S.L.

Abstract An editorial published in April 2022 discusses the benefits and pitfalls of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) combined with intra-aortic balloon pumps (IABP) to manage CS. The complete manuscript,..

Perfusfind S.L.

Abstract The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) following acute myocardial infarction with cardiogenic shock (AMI-CS) is increasing, but the ability to predict favorable outcomes with support remains limited...

Perfusfind S.L.

Abstract Although mechanical circulatory support (MCS) has been used to support patients with cardiogenic shock (CS) for many years, recent advances in device technology, together with the lackluster performance of..

Perfusfind S.L.

Abstract Background As utilization of veno-arterial  (VA-ECLS) in treatment of  (CS) continues to expand, clinical variables that guide clinicians in early recognition of myocardial recovery and therefore, improved survival, after VA-ECLS are..

Perfusfind S.L.

Abstract In patients with severe cardiogenic shock, temporary mechanical circulatory support has become a viable strategy to bridge patients to heart transplantation. However, end-stage heart failure is often associated with progressive organ..

Perfusfind S.L.

Abstract Background and Aim of the Study Acute cardiovascular failure remains a leading cause of death in severe poisonings. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used as a..

Perfusfind S.L.

Abstract Background Cardiac surgery is associated with a high rate of blood use. The aim of this study is to identify preoperative patient factors associated with allogeneic Red Blood Cell..

Perfusfind S.L.

Abstract This study evaluated differences in efficacy and safety outcomes with bivalirudin compared with unfractionated heparin (UFH) in patients with cardiogenic shock requiring venoarterial extracorporeal membrane oxygenation (VA ECMO). We..

Perfusfind S.L.

Abstract Objective Myocardial damage occurs in up to 25% of coronavirus disease 2019 (COVID-19) cases. While veno-venous extracorporeal life support (V-V ECLS) is used as respiratory support, mechanical circulatory support..

Perfusfind S.L.

Abstract Background Venoarterial extracorporeal membrane oxygenation (V-A ECMO) with femoral access has gained wide acceptance in the treatment of critically ill patients. Since the patient´s cardiac output (CO) can compete..

Perfusfind S.L.

Abstract Background Patients with cardiogenic shock or cardiac arrest undergoing venoarterial extracorporeal membrane oxygenation (V-A ECMO) frequently present with blood glucose levels out of normal range. The clinical relevance of..

Perfusfind S.L.

Abstract Aims Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used to support patients in cardiogenic shock (CS). Early determination of disposition is paramount, as longer durations of support have..

Perfusfind S.L.

Abstract Background: Initiation of veno-arterial (VA) Extracorporeal Membrane Oxygenator (ECMO) is associated with severe complications. It is unknown whether these adverse consequences occur more often after initiations during out of..

Perfusfind S.L.

Abstract Background and Objectives:  Cardiogenic shock (CS) is a medical emergency associated with a high mortality rate. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has become an accepted therapy for CS. Despite..

Perfusfind S.L.

Abstract Background: With the rapid development of mechanical circulatory support technologies, patients presenting with cardiogenic shock have gained access to various treatment opportunities which were not until recently available. The Impella®..

Perfusfind S.L.

Abstract Importance  The optimal approach to the use of venoarterial extracorporeal membrane oxygenation (ECMO) during cardiogenic shock is uncertain. Objective  To determine whether early use of moderate hypothermia (33-34 °C) compared with..

Perfusfind S.L.

Abstract Introduction Propofol infusion syndrome (PRIS) is a rare entity that could lead to profound cardiogenic shock (CS). Mitochondrial toxicity and sympathetic blockade are the mechanisms leading to CS in..

Perfusfind S.L.

The ELSO Interim Guidelines for venoarterial extracorporeal membrane oxygenation (VA ECMO) is timely. I would like to raise a few points on weaning recommendations. First, the parameters detailed in Figure 11..

Perfusfind S.L.

Abstract The Impella CP (Abiomed Inc., Danvers, MA) is widely used in cardiac catheterization laboratories for patients presenting with cardiogenic shock, but it is also known to cause significant hemolysis. The risk..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenator (ECMO) is effective for maintaining oxygenation and hemodynamic support in patients with post-cardiotomy cardiogenic shock (PCCS). Researchers, led by Ahmed Abdeljawad, sought to compare the effect..

Perfusfind S.L.

Abstract Background Report the incidence and results of peri-operative extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pump (IABP) of patients undergoing mitral valve surgery (MVS) through right mini-thoracotomy (RT) and..